Top 5 Most Read RNS's on Vox Markets for Monday 9th January 2023
Episode 1112, Jan 09, 2023, 07:48 AM
Top 5 Most Read RNS's on Vox Markets for Monday 9th January 2023
5. Osirium Technologies #OSI - Full Year Trading Update
The Board expects to report bookings and revenue for the 12 months to 31 December 2022 of at least £3.0 million (2021: £1.6 million) and £1.9 million (2021: £1.4 million) respectively, in line with recently upgraded market expectations.
4. Nanoco Group #NANO - Litigation Settlement Update
The settlement process requires further negotiations and continues to operate within the control of the US judicial system, and hence the outcome of the litigation, its settlement, and timing are not wholly within the control of the Parties. As a result of these factors, the value and terms of any final agreement are not yet certain.
The Company expects to issue a further update on the final agreement following the completion of the further negotiations between the Parties.
3. Deepverge #DVRG - 2022 Revenue Update
DeepVerge plc announces that the Company's unaudited revenues for 2022 were approximately £17.2m, slightly below market expectations, although £18m would have been achieved but for a significant element of recently signed contracts now falling for delivery in the current year.
2. Poolbeg Pharma #POLB - Positive Initial Data Analysis in POLB 001 Trial
Early data read out indicates a successful LPS human challenge trial in which POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo.
1. Hemogenyx Pharma #HEMO - Single CBR Can Treat Multiple Viruses
The Company's scientists have identified a target protein that can be incorporated into a single multipurpose CBR-based therapeutic capable of treating multiple viruses that belong to different viral families, instead of having to make a separate CBR construct for every virus.
5. Osirium Technologies #OSI - Full Year Trading Update
The Board expects to report bookings and revenue for the 12 months to 31 December 2022 of at least £3.0 million (2021: £1.6 million) and £1.9 million (2021: £1.4 million) respectively, in line with recently upgraded market expectations.
4. Nanoco Group #NANO - Litigation Settlement Update
The settlement process requires further negotiations and continues to operate within the control of the US judicial system, and hence the outcome of the litigation, its settlement, and timing are not wholly within the control of the Parties. As a result of these factors, the value and terms of any final agreement are not yet certain.
The Company expects to issue a further update on the final agreement following the completion of the further negotiations between the Parties.
3. Deepverge #DVRG - 2022 Revenue Update
DeepVerge plc announces that the Company's unaudited revenues for 2022 were approximately £17.2m, slightly below market expectations, although £18m would have been achieved but for a significant element of recently signed contracts now falling for delivery in the current year.
2. Poolbeg Pharma #POLB - Positive Initial Data Analysis in POLB 001 Trial
Early data read out indicates a successful LPS human challenge trial in which POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo.
1. Hemogenyx Pharma #HEMO - Single CBR Can Treat Multiple Viruses
The Company's scientists have identified a target protein that can be incorporated into a single multipurpose CBR-based therapeutic capable of treating multiple viruses that belong to different viral families, instead of having to make a separate CBR construct for every virus.